BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhao Y, Bilal M, Raza A, Khan MI, Mehmood S, Hayat U, Hassan STS, Iqbal HMN. Tyrosine kinase inhibitors and their unique therapeutic potentialities to combat cancer. Int J Biol Macromol 2021;168:22-37. [PMID: 33290765 DOI: 10.1016/j.ijbiomac.2020.12.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
Number Citing Articles
1 Tasso B, Spallarossa A, Russo E, Brullo C. The Development of BTK Inhibitors: A Five-Year Update. Molecules 2021;26:7411. [PMID: 34885993 DOI: 10.3390/molecules26237411] [Reference Citation Analysis]
2 Hassan RA, Hamed MI, Abdou AM, El-dash Y. Novel antiproliferative agents bearing substituted thieno[2,3-d]pyrimidine scaffold as dual VEGFR-2 and BRAF kinases inhibitors and apoptosis inducers; design, synthesis and molecular docking. Bioorganic Chemistry 2022;125:105861. [DOI: 10.1016/j.bioorg.2022.105861] [Reference Citation Analysis]
3 Zhao Y, Bilal M, Qindeel M, Khan MI, Dhama K, Iqbal HMN. Nanotechnology-based immunotherapies to combat cancer metastasis. Mol Biol Rep 2021;48:6563-80. [PMID: 34424444 DOI: 10.1007/s11033-021-06660-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
4 Wang Y, Du J, Liu Y, Yang S, Wang Q. microRNA-301a-3p is a potential biomarker in venous ulcers vein and gets involved in endothelial cell dysfunction. Bioengineered 2022;13:14138-58. [PMID: 35734851 DOI: 10.1080/21655979.2022.2083821] [Reference Citation Analysis]
5 Tibor Fekete J, Győrffy B. A unified platform enabling biomarker ranking and validation for 1,562 drugs using transcriptomic data of 1,250 cancer cell lines. Computational and Structural Biotechnology Journal 2022. [DOI: 10.1016/j.csbj.2022.06.007] [Reference Citation Analysis]
6 Elkamhawy A, Lu Q, Nada H, Woo J, Quan G, Lee K. The Journey of DDR1 and DDR2 Kinase Inhibitors as Rising Stars in the Fight Against Cancer. Int J Mol Sci 2021;22:6535. [PMID: 34207360 DOI: 10.3390/ijms22126535] [Reference Citation Analysis]
7 Jiao Y, Gao Y, Wang J, An H, Xiang Li Y, Zhang X. Intelligent porphyrin nano-delivery system for photostimulated and targeted inhibition of angiogenesis. International Journal of Pharmaceutics 2022. [DOI: 10.1016/j.ijpharm.2022.121805] [Reference Citation Analysis]
8 Moosavi F, Damghani T, Ghazi S, Pirhadi S. In silico screening of c-Met tyrosine kinase inhibitors targeting nucleotide and drug-substrate binding sites of ABCB1 as potential MDR reversal agents. J Recept Signal Transduct Res 2022;:1-13. [PMID: 35704515 DOI: 10.1080/10799893.2022.2086988] [Reference Citation Analysis]
9 Ferrari E, Naponelli V, Bettuzzi S. Lemur Tyrosine Kinases and Prostate Cancer: A Literature Review. Int J Mol Sci 2021;22:5453. [PMID: 34064250 DOI: 10.3390/ijms22115453] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Brautigan DL, Farrington C, Narla G. Targeting protein phosphatase PP2A for cancer therapy: development of allosteric pharmaceutical agents. Clin Sci (Lond) 2021;135:1545-56. [PMID: 34192314 DOI: 10.1042/CS20201367] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Liang J, Wang S, Zhang G, He B, Bie Q, Zhang B. A New Antitumor Direction: Tumor-Specific Endothelial Cells. Front Oncol 2021;11:756334. [PMID: 34988011 DOI: 10.3389/fonc.2021.756334] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Mao Y, Qamar M, Qamar SA, Khan MI, Bilal M, Iqbal HM. Insight of nanomedicine strategies for a targeted delivery of nanotherapeutic cues to cope with the resistant types of cancer stem cells. Journal of Drug Delivery Science and Technology 2021;64:102681. [DOI: 10.1016/j.jddst.2021.102681] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
13 He X, Liao Y, Liu J, Sun S. Research Progress of Natural Small-Molecule Compounds Related to Tumor Differentiation. Molecules 2022;27:2128. [PMID: 35408534 DOI: 10.3390/molecules27072128] [Reference Citation Analysis]
14 Cui Y, Li Y, Li X, Fan L, He X, Fu Y, Dong Z. A Simple UPLC/MS-MS Method for Simultaneous Determination of Lenvatinib and Telmisartan in Rat Plasma, and Its Application to Pharmacokinetic Drug-Drug Interaction Study. Molecules 2022;27:1291. [PMID: 35209080 DOI: 10.3390/molecules27041291] [Reference Citation Analysis]